title: Relevance of pretransplant donor-specific T cell allorepertoire for human kidney graft survival.
abstract: In order to determine whether the donor-specific T cell allorepertoire evaluated in patients before transplantation can be predictive for kidney graft survival, a study has been set up in which the number and activation state of donor-specific T lymphocytes before transplantation were correlated to transplant survival time. Limiting dilution analysis assays were carried out to determine precursor frequencies of both T helper and cytotoxic T lymphocytes. The activation state of these cells was studied by evaluating the inhibitory capacity of cyclosporine on helper and cytotoxic T cells and/or a monoclonal antibody directed against CD8 on cytotoxic T cells. This study shows that neither a significant difference in the number nor activation state of donor-directed helper and cytotoxic T cells before transplantation could be detected when patients who acutely rejected their grafts were compared with patients who still had a well-functioning kidney graft after more than 10 years. Moreover, no significant differences in the donor-specific T cell repertoire were found when patients who had been subject to multiple rejection episodes were compared with patients who experienced few complications after transplantation. Therefore, we conclude that in individuals who have not been sensitized to HLA antigens of the donor, the donor-specific peripheral T cell allorepertoire prior to transplantation is not predictive of kidney graft survival.
authors.affiliation: Department of Immunohematology, Leiden University Hospital, The Netherlands.
authors.forename: G J
authors.initials: GJ
authors.lastname: Bouma
authors.forename: E M
authors.initials: EM
authors.lastname: van der Meer-Prins
authors.forename: F J
authors.initials: FJ
authors.lastname: van der Woude
authors.forename: J J
authors.initials: JJ
authors.lastname: van Rood
authors.forename: F H
authors.initials: FH
authors.lastname: Claas
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D016827:CD8 Antigens / Q000276:immunology; D016572:Cyclosporine / Q000494:pharmacology; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation; D018655:Lymphocyte Count / Q000187:drug effects; D013234:Stem Cells / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D000906:Antibodies; D016827:CD8 Antigens; D016572:Cyclosporine